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cohort of French gendarmes
Hafiz Muhammad Yaseen1,2, Fabrice Simon3, Xavier Deparis1,2 and Catherine Marimoutou1,2*Abstract
Background: The objective was to identify severity characteristics of initial chikungunya infection (CHIKV) stages
associated with post-CHIKV arthritis and arthralgia.
Methods: French gendarmes exposed to the 2005–2006 CHIKV epidemic in Reunion Island who completed the
2006 (self-reporting acute and early chronic [median: 6 months] symptoms) and 2008 (Endpoint [median:
30 months]: self-perceived recovery and rheumatic disorders (RDs)) surveys were included. Multinomial logistic
regression and multiple correspondence analysis (MCA) were used. Arthralgia was defined by joint pain and/or
stiffness and arthritis by joint swelling in addition to pain and/or stiffness.
Results: In 2008, 124 (31.3%)/403 participants (101 CHIKV+/302 CHIKV-) reported arthralgia and 57 (14.1%) arthritis.
The multivariate model kept CHIKV infection, comorbidity and acute stage depressed mood as independent
prognostic factors for both arthralgia and arthritis, but found early chronic stage RD as the main determinant of the
same RD two years later.
The MCA performed with the 85 CHIKV + patients who answered the question on self-perceived recovery enabled
the calculation of severity scores based on initial symptoms that were strongly associated with persistent arthritis
and, to a lesser extent, to arthralgia in bivariate analyses. The MCA graph clearly distinguished arthritis as the only
RD associated with early severity indicators represented by sick leave, joint swelling and depressed mood during
the acute stage, and early chronification of arthritis and depressed mood.
Conclusion: Initial CHIKV severity predicted recovery, with higher severity associated with arthritis and lower
severity with arthralgia. More interestingly, specific markers of post-CHIKV arthritis, which can easily be used by
clinicians for case management, were identified.
Keywords: Chikungunya, Arthritis, Arthralgia, Recovery, Multiple correspondence analysis, Severity scoreBackground
Chikungunya infection (CHIKV) is a self-limiting,
two-stage disease caused by an Aedes mosquito-transmitted
virus. The CHIKV acute stage typically consisting of fever,
rash and multiple joint disorders is frequently followed by a
chronic stage, mainly characterized by peripheral joint
disorders [1-9], which it is estimated can persist up to five
years [10]. Different studies have investigated prognostic
factors of CHIKV non-recovery, generally assimilating* Correspondence: marimoutouc@aol.com
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unless otherwise stated.non-recovery with the persistence of rheumatic disorders,
but with non-standardized definitions of either “recovery”
or “post-CHIKV rheumatic disorders” [3,11,12]. Moreover,
if a severe acute stage of CHIKV was reported to be
associated with persistent rheumatic disorders, no
standard definition of severity was used [6,8,13]. No
prognostic study distinguished between arthralgia and
arthritis, although this distinction makes sense in
terms of management. While arthralgia is the most
common post-CHIKV rheumatic disorder (RD), arthritis
is much more incapacitating and can be the first step
towards destructive inflammatory rheumatism [14,15].
Thus, the identification of specific prognostic factors forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yaseen et al. BMC Musculoskeletal Disorders 2014, 15:249 Page 2 of 8
http://www.biomedcentral.com/1471-2474/15/249post-CHIKV arthritis should be of interest as an aid
to therapeutic decision-making to control the inflam-
mation process early enough before any joint destruc-
tion occurs, as has recently been proposed by some
rheumatologists [15,16].
In a previous study, we observed that, in a cohort of
French gendarmes (members of a French military force
responsible for carrying out police duties among civilian
populations), CHIKV-infected patients (CHIKV+) presented
a higher frequency and intensity of joint disorders and an
impaired quality of life 30 months after infection, whether
they self-considered themselves recovered or not, than
non-infected (CHIKV-) subjects [2]. The objective of
the present study was to identify specific prognostic factors
of persistent arthritis in the same cohort, focusing on
the symptoms of infection during the initial stages of
the disease. In order to take into account the patients’
perception of the disease, the association of these factors
with self-perceived recovery was also studied.
Methods
Ethical aspect
This study is based on data collected retrospectively at
two different times among the same population of
gendarmes. A major outbreak of CHIKV in Reunion
Island ended in June 2006. In that context, it was decided
that a study on the prevalence and consequences of infec-
tion among gendarmes would be conducted, because
CHIKV was considered to be a possible work-related
disease. All the gendarmes on duty in Reunion Island were
offered a serological test for CHIKV and self-report ques-
tionnaires by their military physician. Testing was consid-
ered to be part of routine care, but patients were informed
about the study by a written notice attached to the self-
questionnaire and the military physician received their
oral consent before inclusion. Only those who accepted
the blood test and questionnaire were included. In 2008,
follow-up questionnaires were offered to each participant
of the 2006 study. Questionnaires were sent out by mail
with written information on the study’s aim, which
explained that it was an anonymous epidemiological study
and instructed patients who agreed to participate, to send
back the completed questionnaire using the pre-identified
attached envelope. The two thirds of the patients who
returned the questionnaires with self-reported, hand-
written data were thus considered to have consented to
participate in the study. Both the studies and their consent
procedures were approved by the Clinical Research
Committee of the Central Directorate of the Army Health
Service (DCSSA). Data were analyzed anonymously.
Study population and definitions
The study population was made up of the French
gendarmes who completed both the 2006 survey (n = 662)[1] and the 2008 survey (n = 404) [2], minus one subject
excluded for redundant data. The 259 non-respondents in
2008 did not differ from the 403 included in terms of
proportion of CHIKV-infected patients, sex and age.
In accordance with previous studies performed on the
same cohort [1,2], and due to the fact that serology results
were highly concordant with self declaration; subjects
were considered CHIKV + (n = 101) or CHIKV- (n = 302)
according to their self declaration.
In both the 2006 and 2008 studies, participants were
asked to mention which joints presented pain, stiffness
or swelling at different times. To distinguish between
arthralgia and arthritis, rheumatic disorders were classified
in three categories: 1) no rheumatic disorders, if no pain,
stiffness or swelling was reported, 2) arthralgia, if only
joint pain and/or stiffness was reported, 3) arthritis, if joint
swelling was reported in addition to pain and/or stiffness,
regardless of the number of joints involved.
Data on initial CHIKV stages were those collected in the
2006 survey, which concerned acute stage symptoms and
those persisting at the time of the survey (i.e. a median
lapse of six months after CHIKV infection), the latter being
called symptoms of the “early chronic stage” or “early
chronic symptoms”. Clinical symptoms of the acute stage
(fever, rash, joint pain, joint swelling, muscle pain, head-
ache) were taken into account as dichotomous variables
coded “yes” for present and “no” for absent. As fever was
common, the level of fever (>39° or ≤39° according to the
median), and its duration (>or ≤ 2 days [median duration])
were added. Asthenia was coded “yes” if it was self-
evaluated as “quite significant”, “significant”, “very signifi-
cant” or “totally disabling” on the 6-item Likert scale, and
“no” if evaluated as “absent” or “minor”, and mood was
coded “depressed” if it was self-evaluated as “affected” or
“totally depressed” on the 4-item Likert scale, and “not
depressed” if it was evaluated as “normal or weak but
confident”. The notion of sick leave during the acute stage
was added using two variables: sick leave (yes/no) and
duration of sick leave (≤4 days or >4 days; [4 days =median
duration]). Three items for the early chronic stage were
kept: joint disorders (categorized as no rheumatic disor-
ders/arthralgia/arthritis); asthenia (yes, no) and depressed
mood (yes, no), using the same cut-off as that used on the
Likert scales.
As age and rheumatic comorbidity have been associated
with recovery in different studies [3,11,12], we also
integrated in the models age (coded: ≤ 40 and >40 years,
according to the median age of the participants in 2006),
and a “comorbidity” variable coded “yes” if the patient had
reported a history of “traumas in tendons, joints or bones”
or “osteo-articular diseases”.
Finally, self-perceived recovery was defined by the
answer “yes” or “no” to the 2008 survey question: “Do you
consider yourself recovered?”.
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To identify the prognostic factors associated with
persistent arthralgia or arthritis 30 months after infection
(median duration of follow-up in 2008), we first analyzed
the entire 2008 study sample using a multinomial logistic
regression with “no rheumatic disorders” as the reference
category. To implement the regression model, all
the predictive variables were first assessed individually
using univariate regression models. Then, variables
with a significant p-value < 0.20 were included in the
multivariate regression model, and a backward stepwise
procedure was used to keep as predictors the variables
with p-value <0.05. These regressions were performed
using STATA software, version 9.
The CHIKV acute stage symptoms were largely shared
by CHIKV + patients and absent in CHIKV- patients.
This led to interactions and colinearity in the multivariate
regression model. Identifying the independent predictive
role of CHIKV infection in RDs was of epidemiological
interest and keeping CHIKV- subjects in the study in-
creased the power of the study, but with regard to the
identification of CHIKV initial symptoms of severity that
could help manage CHIKV + patients, keeping CHIKV-
patients in analyses was useless. Thus, our second step
was to focus on CHIKV + patients, and in order to avoid
interaction and colinearity problems, a multiple corres-
pondence analysis (MCA) was used. With the help of
MCA, we sought to estimate predictors of both rheumatic
disorders (separately for arthralgia and arthritis) and self-
estimated recovery, but also to find a standardized
definition of severity of early CHIKV infection which
would be easy to identify and reproduce by clinicians. For
these analyses, XL-Stat 9 and R 2.15.1 softwares were
used.
The MCA displays the individuals and variable
categories as labeled points in a multiple dimensional
space. It decomposes all the information represented by
variables and individuals into multiple factorial axes,
such that each successive factorial axis captures a part of
the total information in decreasing order [17]. Thus, the
first two factorial axes capture the maximum amount of
information available in the data. With the help of these
two factorial axes, the graphic display of variable
categories can reveal the structural relation between
variables. In the graph, the more distant a variable
category is from the origin, the higher its contribution is
(i.e. the contribution of categories near the origin is
small), but outliers situated too far from the origin are
no longer informative. In the study, sex categories were
thus excluded as there were only 3 females, which led to
a distortion of the MCA graph (the category “women”
representing an outlier that was too far from the origin).
Most interestingly, the interpretation of data associations
can easily be read on the MCA graph: the closer thevariable categories are on the graph, the stronger they
are associated. Here, the categories of self-perceived
recovery at 30 months and rheumatic disorders were
superimposed on the MCA graph to observe which
symptoms were closer to (i.e. were associated with)
self-perceived recovery, arthralgia and arthritis. The
strength of these associations was tested in binary
analyses using the Chi2 test.
One property of MCA is the possibility of providing a
severity scale from 0 (corresponding to the theoretically
least severe case) to 100 (corresponding to the theoretically
most severe case) for each factorial axis [18]. The score is
calculated using the following formula: [1-(X-Xmin)/
(X-Xmax)]*100, where X = coordinate of an individual
on a factorial axis F, Xmin = minimum coordinate on
F, Xmax = maximum coordinate on F.
This formula was used to calculate 3 severity scores
based on the MCA coordinates of variables on the first
factorial axis, which was the most informative. The first
score was calculated using both acute and early chronic
stage symptoms, the second using only the acute symptoms
and the third using only the early chronic symptoms.
Associations between these scores and self-perceived
recovery, arthritis and arthralgia at 30 months were
also tested using Kruskal-Wallis tests.
Results
Multinomial regression analysis results
In 2008, 124 (31.3%) of the 403 participants reported
arthralgia and 57 (14.1%) arthritis. It was more likely
that they were CHIKV + than gendarmes with no RDs: 6
times more likely when reporting arthralgia and 11 times
more when reporting arthritis. In addition, in the univari-
ate analysis, all symptoms of initial CHIKV stages were
significantly associated with persistent rheumatic disorders
at 30 months, especially the rheumatic disorders of the
early chronic stage. Arthralgia during the early chronic
stage was 14 times more frequent in patients presenting
arthralgia or arthritis in 2008 than in those with “no
rheumatic disorders”. Arthritis at six months was 10 times
more frequent in patients complaining of arthritis than in
those complaining of arthralgia in 2008, and 40 times more
frequent when comparing the 2008 arthritis group to
the “no RDs” group. Moreover, patients with rheumatic
disorders in 2008 also declared rheumatic comorbidities
1.3 times more frequently.
The final multivariate model excluding the early chronic
stage symptoms kept the following as independent
prognostic factors: CHIKV infection, comorbidity and
acute stage depressed mood for both persistent arthralgia
and arthritis. When the early chronic symptoms were
added to the model, the role of the acute stage symptoms
disappeared in favor of a strong association between the
rheumatic disorders present during the early chronic stage
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2008; Table 1).
MCA analysis results
For this analysis, the 16/101 CHIKV + non-responders
to the question on recovery were excluded. The study
sample was therefore 85 patients, 48 (56%) declaring
themselves recovered in 2008 and 37 (44%) not recovered.
Patients were 82/85 (96.5%) male and the median age was
40 years (range: 21–54 years) at disease onset. During the
acute stage, 60 patients (71%) reported fever, 42 (49%)
fever >39°C and 41 (49%) fever duration >2 days; 40 (47%)
reported rash, 39 (46%) joint pain, 32 (38%) joint swelling,
45 (53%) muscle pain, 48 (57%) headache, 48 (57%) sick
leave due to CHIKV infection (38 [45%] for more than
4 days), 62 (73%) reported significant asthenia and 30
(35%) depressed mood. During the early chronic stage, 35
(42%) patients reported arthralgia, 29 (33%) arthritis,
45 (53%) significant asthenia and 32 (38%) depressed
mood. In 2008, 13 (15%) patients reported no RDs, 33
(39%) reported arthralgia and 39 (46%) arthritis.
The MCA results are presented in Figure 1. Factorial
axis 1 captured 93.1% of the variability and clearly distin-
guished the presence of initial CHIKV symptoms on the
left from absence on the right. Age, sex and comorbidity
did not participate in severity scores as they were not sig-
nificantly associated with axis 1, but only poorly associated
with axis 2. It can be seen in Figure 1 that age and comor-
bidity categories are close to the origin of the axes.
The bivariate analysis testing the association between
three severity scores calculated on axis 1 and rheumatic
symptoms is summarized in Table 2 and in Table 3
for self-perceived recovery. The three scores were
significantly associated with any persistent rheumatic
disorders, but the median scores were higher and the
association stronger with arthritis than with arthralgiaTable 1 Prognostic factors associated with rheumatic sympto
n = 403 (Multinomial Logistic Regression Analysis)
Multivariate analysis (without early chronic s
Reference: no rheumatic disorders OR (9
Arthralgia Arthrit
CHIKV Infection 4.67 (2.32-9.41)ǂ 26.75 (11.15-
Comorbiditya 2.00 (1.25-3.20)ǂ 2.47 (1.19-
Symptoms at acute stage
Depressed moodb 8.90 (1.06-74.95)* 13.92 (1.66-1
Symptoms at early chronic stage (median: 6 months after infection)
Arthralgiac - -
Arthritisd - -
*p < 0.05; ǂp < 0.005; OR: odds ratio; CI: confidence interval.
aHistory of at least one of the following pathologies: sprain or dislocation of joints o
bSelf-assessed mood coded as “depressed” if checked affected or totally depressed.
cArthralgia = joint pain and/or stiffness.
dArthritis = swelling in addition to joint pain and stiffness.(Table 2). Only the early chronic stage score was
associated with self-perceived non-recovery (Table 3).
According to the MCA graph (Figure 1), the following
symptoms: sick leave, its duration >4 days, joint swelling
and depressed mood during acute stage, in addition to
early chronic arthritis and depressed mood, circled in the
upper left corner of Figure 1, were closely associated with
persistent arthritis at 30 months and self-perceived non-
recovery at that time (categories close to each other in the
same circle). Arthralgia at 30 months was projected in the
right lower quarter of the graph, i.e. on the side of “no or
mild” symptoms of initial CHIKV infection.
The strong association of the circled symptoms with
arthritis at 30 months was confirmed by bivariate Chi2
analysis (Table 4). The associations were weaker with
self-perceived non-recovery, and not confirmed for acute
stage sick leave >4 days and acute joint swelling (Table 5).
Discussion
Both analyses underlined the determinative role of acute
depressed mood and early chronification of arthritis in
the risk of persistent arthritis at 30 months. However,
when CHIKV- patients were taken into account
(multiple regression model), the main determinants
of long-term rheumatic disorders whether inflammatory
or not were CHIKV infection and underlying rheumatic
comorbidities. The MCA restricted to CHIKV + patients
enabled us to demonstrate that CHIKV initial symptoms
were highly interrelated, and to calculate severity scores
that were strongly associated with persistence of arthritis
after 30 months. Moreover, it made it possible to isolate
simple initial severity indicators easily identifiable by clini-
cians for patient management, such as long sick leave and
joint swelling during the acute stage, in addition to chronifi-
cation of depressed mood and arthritis at six months.
Although long term arthralgia was linked to underlyingms in 2008, cohort of French Gendarmes (2006–2008),
ymptoms) Multivariate analysis (with early chronic symptoms)
5% CI) Reference: no rheumatic disorders OR (95% CI)
is Arthralgia Arthritis
64.17)ǂ 2.58 (1.05-6.38)* 10.56 (3.42-32.63)ǂ
5.14)* 2.03 (1.26-3.27)ǂ 2.27 (1.06-4.87)*
16.88)* - -
8.64 (1.95-38.17)ǂ 6.65 (1.33-33.30)*
2.93 (0.47-18.18) 19.38 (3.36-111.82)ǂ
r bones and joint diseases, before CHIKV infection.
Figure 1 Multiple Correspondence Analysis graph with CHIKV acute and early chronic stage symptoms, Cohort of French CHIKV+
Gendarmes (2006–2008, N = 85). Legend: Rheum6-0, Rheum6-1, Rheum6-2 = respectively No rheumatic disorders, arthralgia, arthritis at 6
months; P1 = acute stage; P2 = early chronic stages; D = duration; M = maximum; y = yes; n = no; Workstop: sick leave. depMood: depressed
mood; Supp. variables=supplementary variables=recovery (y-healed/n-healed) and rheumatic symptoms at 30 months (Rheum30-0, Rheum30-1,
Rheum30-2 = respectively No rheumatic disorders, arthralgia, arthritis at 30 months).
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find it to be associated with CHIKV severity.
The association between severity of the acute CHIKV
stage and persistent rheumatic disorders has already
been described by some studies [6,8,13]. But the present
study is the first to quantify the overall severity of
the acute and early chronic stages of CHIKV infection
in the form of severity scores, and thus to objectify
the association between initial severity and long-term
post-CHIKV rheumatic disorders and self-perceived
recovery. These scores showed that severity of both
acute and early chronic stages of CHIKV infection
was associated with long-term rheumatic disorders.
However, the association was much stronger and theTable 2 Distribution of initial severity scores calculated with
analysis according to rheumatic disorders reported by CHIKV
(2006–2008)
No rheumatic disorder
N = 13 (15.3%)
Median overall severity score (IQ) 0 (0–39.7)
Median acute stage severity score (IQ) 0 (0–43.3)
Median early chronic stage severity score (IQ) 0 (0–61.7)
IQ: interquartile 25%-75%.
*Kruskal-Wallis test comparing the distribution of severity scores according to rheum
dArthralgia = joint pain and/or stiffness. Arthritis = swelling in addition to joint painseverity scores higher for long-term arthritis than for
arthralgia, suggesting that the more severe the initial
CHIKV infection, the more likely it was that patients
would develop long-term arthritis. At a mild level of
severity, they would develop arthralgia (with a far lower
risk of joint destruction), and at a lower level no
rheumatic consequence. The location of 30-month
arthralgia on the MCA graph confirmed this hypothesis.
In addition, our study is the first to distinguish
common arthralgia from arthritis among post-CHIKV
rheumatic disorders, which made it possible to identify
specific prognostic factors of arthritis. In a recent study,
Gérardin et al. [19] distinguished relapsing post-CHIKV
rheumatic musculoskeletal pain (RMSP) from lingeringthe first factorial axis of the multiple correspondence
+ patients in 2008 (N = 85), cohort of French Gendarmes
sd Arthralgiad p* Arthritisd p*
N = 33 (38.8%) N = 39 (45.9%)
60.8 (22.3-79.6) 0.024 73.2 (60.9-82.3) 0.001
60.0 (24.9-78.8) 0.042 75.4 (56.5-82.0) 0.002
61.7 (31.1-89.1) 0.025 72.6 (50.3-100.0) 0.001
atic symptoms, considering “No rheumatic disorders” as reference.
and stiffness.
Table 3 Distribution of initial severity scores calculated
with the first factorial axis of the multiple correspondence
analysis according to self-perceived recovery status of







Median overall severity score (IQ) 55.6 (0–78.7) 70.7 (49.1-79.6) 0.098
Median acute stage severity
score (IQ)
58.0 (0–78.5) 67.0 (44.5-79.0) 0.202
Median early chronic stage
severity score (IQ)
58.5 (0–72.6) 72.6 (58.5-100) 0.006
IQ: interquartile 25%-75%.
*Kruskal-Wallis test comparing the distribution of severity scores according
to recovery.
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found that age and initial severity (defined by severe
rheumatic involvement and level of CHIKV IgG titers dur-
ing the acute phase) were predictive of both lingering and
relapsing RMSP [19]. The distinction based on intensity of
rheumatic disorders, arthritis being more severe than
arthralgia, seems more relevant, since it made it possible
to isolate specific predictors and has consequences for pa-
tient management, in particular for therapeutic decisions
[15,16]. The study was based on self-reported symptoms,
so the diagnosis of arthritis cannot be certain. However,
after discussion with clinicians, swelling was considered
specific enough to synovitis to warrant proposing this dis-
tinction. Moreover, the consistency of data between 2008
and 2006, as well as with incapacitation reported on theTable 4 Bivariate analysis (Chi2 test) testing the association b
associated with long-term arthritis on the MCA Graph and rh
CHIKV + Patients (N = 85), Cohort of French Gendarmes (2006
No rheumatic disorders
N = 13 (15.3%)
Comorbiditya 4 (30.8)
Symptoms at acute stage -
Sick leave (yes) 3 (23.1)
Duration of absence from work >4 days 2 (15.4)
Joint swelling (yes) 2 (15.4)
Depressed moodb -





*χ2 test of comparison between No rheumatic disorders and Arthralgia.
**χ2 test of comparison between No rheumatic disorders and Arthritis.
aHistory of at least one of the following pathologies: sprain or dislocation of joints o
bSelf-assessed mood coded as “depressed” if checked affected or totally depressed.
cArthralgia = joint pain and/or stiffness. Arthritis = swelling in addition to joint painquality of life SF-36 questionnaire completed in 2008
(data not shown), reinforced the reliability of patients’
declarations.
The MCA graph enabled an easy visual identification
of associations between certain symptoms and long-term
arthritis or self-perceived non-recovery. Some of the
symptoms identified, such as joint swelling during the
acute stage, have already been reported as being associ-
ated with CHIKV recovery [11], but with a different def-
inition of recovery. In our results, there was a clear
continuum in the inflammatory symptoms, as swelling
in the acute stage was also found in the early and late
chronic stages of CHIKV. Depression was reported to be
frequent after CHIKV infection [2,4]. In our study, de-
pressed mood during both acute and early chronic stages
were prognostic of both persistence of arthritis at
30 months and self-reported non-recovery. This link
suggests that attention should be paid to this symptom,
which may be indicative of either the severity of the dis-
ease or the patient’s anxiety concerning delay in recov-
ery. However, a direct action of the CHIK virus on the
brain should be explored.
The MCA found other indirect markers of severity as-
sociated with long-term arthritis, such as absence from
work and its duration. This is consistent with the notion
that the more severe the acute stage is, the greater the
risk will be to develop arthritis. Last but not least,
reporting arthritis during the early chronic stage was
found to be associated with the long-term persistence of
arthritis, while early arthralgia was not. This was also
found with the multinomial logistic regression, whichetween the initial symptoms of Chikungunya infection
eumatic disorders declared at 30 months by
–2008)
Arthralgiac P* Arthritisc P**
N = 33 (38.8%) N = 39 (45.9%)
16 (48.5) 0.447 25 (64.1) 0.076
- - -
17 (51.5) 0.155 28 (71.8) 0.006
13 (39.4) 0.224 23 (59.0) 0.016
9 (27.3) 0.640 21 (53.9) 0.036
11 (33.3) 0.045 19 (48.7) 0.005
21 (63.6) 0.025 11 (28.2) 0.122
4 (12.1) 0.827 22 (56.4) 0.004
11 (33.3) 0.045 21 (53.8) 0.002
r bones and joint diseases, before CHIK infection.
and stiffness.
Table 5 Bivariate Analysis (Chi2 test) testing the association
between the initial symptoms of Chikungunya infection
associated with non-recovery on the MCA graph and
self-perceived recovery status at 30 months by







Comorbiditya 24 (50.0) 21 (56.8) 0.689
Symptoms at acute stage - - -
Sick leave (yes) 22 (45.8) 26 (70.3) 0.042
Duration of sick leave >4 days 17 (35.4) 21 (56.8) 0.082
Joint swelling 17 (35.4) 15 (40.5) 0.797
Depressed moodb 11 (22.9) 19 (51.4) 0.012
Symptoms at early chronic stage (median: 6 months after infection)
Rheumatic symptomsc
Arthralgia 23 (47.9) 12 (32.4) 1.000
Arthritis 10 (20.8) 18 (48.6) 0.046
Depressed moodc 12 (25.0) 20 (54.1) 0.012
*χ2 test of comparison of distribution of each characteristics between the two
groups.
aHistory of at least one of the following pathologies: sprain or dislocation of
joints or bones and joint diseases, before CHIK infection.
bSelf-assessed mood coded as “depressed” if checked affected or totally depressed.
cArthralgia = joint pain and/or stiffness. Arthritis = swelling in addition to joint
pain and stiffness.
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with late persistent arthralgia and early arthritis with late
arthritis. This fact is of major importance, because it
supports the recommendation that early detection of
persistent arthritis within the first 6 months should be
carried out in order to initiate adequate treatment.
Rheumatologists in Reunion Island and India have
recommended that the treatment should be based on
disease-modifying antirheumatic drugs, with methotrexate
as the first-line therapy to control the inflammation
process before joint destruction occurs [15,16].
In no analysis was age contributive, although it has
been widely reported to be associated with CHIKV
recovery [3,8,11]. This might be due to the specificity
of our population, made up of young, healthy workers,
none of whom were over 55 years of age.
Moreover, according to the MCA, the contribution
of comorbidity was very small, although it was also
frequently reported [3,8,11]. The frequency of previous
musculoskeletal pain or traumatic history among patients
suffering from post-CHIKV rheumatic disorders often led
to the consideration that CHIKV may reveal or stimulate
underlying rheumatic diseases. Our results on the entire
cohort sample are in favor of this conclusion, as the associ-
ation between rheumatic comorbidity and late rheumatic
disorders existed for both infected and non-infectedpatients. It seemed more likely that the association could
be explained by arthralgia, as it was the most frequent
rheumatic disorder when considering CHIKV- subjects
and comorbidity did not contribute to long-term arthritis
according to the MCA.
The two different assessments of recovery (self-perceived
or evaluated by persistent rheumatic disorders at 30 months)
led to differences in the prognostic factors found to be asso-
ciated with recovery. Self-perceived recovery was only asso-
ciated with the severity score based on “early chronic stage”
symptoms, suggesting that the severity of entry into the
chronic stage is the main predictor of the perception of
recovery. Since the question about recovery was asked
30 months after the acute infection, it seems logical that
patients who did not enter the chronic stage (no or few
symptoms reported after six months of infection) consid-
ered themselves recovered regardless of the severity of their
acute stage. On the other hand, most of the subjects who
declared themselves recovered did report rheumatic disor-
ders (35% reported arthralgia and 37% arthritis, data not
shown). They may either have considered that their symp-
toms were not linked to CHIKV or considered that they
were a bearable after-effect. It is therefore up to physicians
to estimate the severity of symptoms and their possible
consequences on joint integrity in order to decide on future
management. The existence of severity characteristics
during the previous stages of CHIKV disease should be an
additional aid to therapeutic decision-making.
Conclusions
The severity of initial stages of CHIKV infection negatively
influences long-term recovery and in particular increases
the risk of long-term arthritis. However, the severity scores
provided by the MCA cannot be directly used by physicians
to predict how the condition of their individual patients will
progress, as they cannot be calculated for a single subject.
For the management of an individual patient’s condition,
asking about the presence of joint swelling, mood depres-
sion and lengthy absence from work during the acute stage
may alert physicians to the risk of arthritis in the medium-
and long-term. The early chronification of arthritis should
lead to further investigations, so that the physician can
make rapid decisions about specific therapies to avoid
long-term persistence and risk of joint destruction.
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